Acrivon CEO to Discuss Oncology Pipeline at TD Cowen Summit
Event summary
- Acrivon Therapeutics CEO Peter Blume-Jensen to participate in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026.
- Company advancing ACR-368 in a registrational intent Phase 2b study for endometrial cancer with FDA Fast Track and Breakthrough Device designations.
- ACR-2316, a WEE1/PKMYT1 inhibitor, showing initial clinical activity in endometrial cancer, SCLC, and sqNSCLC.
- Preclinical candidates targeting CDK11 demonstrating complete tumor regression in aggressive AML models.
The big picture
Acrivon’s participation in TD Cowen’s Oncology Innovation Summit underscores the growing emphasis on precision oncology and AI-driven drug discovery. The company’s AP3 platform differentiates it in the competitive oncology space, but its success hinges on translating preclinical promise into clinical validation. The strategic focus on endometrial cancer and aggressive AML models aligns with unmet needs in these indications, but execution risks remain high.
What we're watching
- Clinical Validation
- How ACR-368's Phase 2b data will impact its registrational path in endometrial cancer.
- Pipeline Progress
- The pace at which ACR-2316 advances through Phase 1/2 trials and demonstrates broader clinical activity.
- Regulatory Strategy
- Whether Acrivon can leverage FDA designations to accelerate approval timelines for its lead assets.
Related topics